Last reviewed · How we verify
Ketofol(ketamine+propofol) — Competitive Intelligence Brief
marketed
Fixed-dose combination anesthetic
NMDA receptor (ketamine); GABA-A receptor (propofol)
Anesthesia
Small molecule
Live · refreshed every 30 min
Target snapshot
Ketofol(ketamine+propofol) (Ketofol(ketamine+propofol)) — Post Graduate Institute of Medical Education and Research, Chandigarh. Ketofol is a fixed-dose combination of ketamine (NMDA receptor antagonist) and propofol (GABA-A agonist) that produces rapid sedation and anesthesia with preserved airway reflexes and hemodynamic stability.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ketofol(ketamine+propofol) TARGET | Ketofol(ketamine+propofol) | Post Graduate Institute of Medical Education and Research, Chandigarh | marketed | Fixed-dose combination anesthetic | NMDA receptor (ketamine); GABA-A receptor (propofol) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Fixed-dose combination anesthetic class)
- Post Graduate Institute of Medical Education and Research, Chandigarh · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ketofol(ketamine+propofol) CI watch — RSS
- Ketofol(ketamine+propofol) CI watch — Atom
- Ketofol(ketamine+propofol) CI watch — JSON
- Ketofol(ketamine+propofol) alone — RSS
- Whole Fixed-dose combination anesthetic class — RSS
Cite this brief
Drug Landscape (2026). Ketofol(ketamine+propofol) — Competitive Intelligence Brief. https://druglandscape.com/ci/ketofol-ketamine-propofol. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab